Epigenetic Dysregulation in Glioblastoma: Potential Pathways to Precision Medicine

Overview

Journal Neurogenetics

Specialty Neurology

Date 2024 Nov 25

PMID 39585441

Authors

Vijeta Prakash

Reema Gabrani

Affiliations

Soon will be listed here.

Abstract

The emerging field of epigenetics has been driving glioblastoma multiforme (GBM) development and progression. Various epigenetic alterations involving tumor suppressor genes, oncogenes, and signaling pathways have been identified in GBM. These alterations contribute to the aggressive behavior, therapeutic resistance, and tumor heterogeneity observed in GBM. Furthermore, the identification of specific genetic mutations associated with epigenetic dysregulation in GBM has provided new insights into the molecular subtypes and potential therapeutic targets within GBM. Understanding the complex interplay between genetic and epigenetic alterations in GBM is crucial for the development of effective and personalized therapies for this devastating disease. This review paper provides an overview of the epigenetic changes occurring in GBM and the potential of targeted epigenetic therapies as a promising avenue for GBM treatment, highlighting the challenges and future directions in this field has been deliberated.

References

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning K . The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med. 2018; 24(10):1611-1624. PMC: 6181207. DOI: 10.1038/s41591-018-0156-x. View

Bernstein B, Stamatoyannopoulos J, Costello J, Ren B, Milosavljevic A, Meissner A . The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010; 28(10):1045-8. PMC: 3607281. DOI: 10.1038/nbt1010-1045. View

Ahuja N, Sharma A, Baylin S . Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med. 2016; 67:73-89. PMC: 4937439. DOI: 10.1146/annurev-med-111314-035900. View

Azad N, Zahnow C, Rudin C, Baylin S . The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013; 10(5):256-66. PMC: 3730253. DOI: 10.1038/nrclinonc.2013.42. View

Zang L, Kondengaden S, Che F, Wang L, Heng X . Potential Epigenetic-Based Therapeutic Targets for Glioma. Front Mol Neurosci. 2018; 11:408. PMC: 6249994. DOI: 10.3389/fnmol.2018.00408. View

Kim Y . Altered histone modifications in gliomas. Brain Tumor Res Treat. 2014; 2(1):7-21. PMC: 4049557. DOI: 10.14791/btrt.2014.2.1.7. View

Li J, Zhu Y, Wang H, Ji X . Targeting Long Noncoding RNA in Glioma: A Pathway Perspective. Mol Ther Nucleic Acids. 2018; 13:431-441. PMC: 6202792. DOI: 10.1016/j.omtn.2018.09.023. View

Zhang S, Zhao B, Zhou A, Lin K, Zheng S, Lu Z . mA Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell. 2017; 31(4):591-606.e6. PMC: 5427719. DOI: 10.1016/j.ccell.2017.02.013. View

10.

Dong Z, Cui H . The Emerging Roles of RNA Modifications in Glioblastoma. Cancers (Basel). 2020; 12(3). PMC: 7140112. DOI: 10.3390/cancers12030736. View

11.

Zhang C, Liang S, Zhang H, Wang R, Qiao H . Epigenetic regulation of mRNA mediates the phenotypic plasticity of cancer cells during metastasis and therapeutic resistance (Review). Oncol Rep. 2023; 51(2). PMC: 10777459. DOI: 10.3892/or.2023.8687. View

12.

Christoph S, Alicia S, Fritz T, Vanessa T, Ralf K, Jin K . The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?. Acta Neurochir (Wien). 2023; 165(6):1635-1644. DOI: 10.1007/s00701-023-05594-7. View

13.

Metais A, Tauziede-Espariat A, Garcia J, Appay R, Uro-Coste E, Meyronet D . Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion. Acta Neuropathol Commun. 2023; 11(1):14. PMC: 9843943. DOI: 10.1186/s40478-023-01506-z. View

14.

Colella B, Faienza F, Di Bartolomeo S . EMT Regulation by Autophagy: A New Perspective in Glioblastoma Biology. Cancers (Basel). 2019; 11(3). PMC: 6468412. DOI: 10.3390/cancers11030312. View

15.

Postwala H, Shah Y, Parekh P, Chorawala M . Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways. Med Oncol. 2023; 40(11):334. DOI: 10.1007/s12032-023-02201-8. View

16.

Wu R, Yun Q, Zhang J, Bao J . Downregulation of KLF13 through DNMT1-mediated hypermethylation promotes glioma cell proliferation and invasion. Onco Targets Ther. 2019; 12:1509-1520. PMC: 6390852. DOI: 10.2147/OTT.S188270. View

17.

Brandes A, Franceschi E, Paccapelo A, Tallini G, de Biase D, Ghimenton C . Role of Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist. 2017; 22(4):432-437. PMC: 5388380. DOI: 10.1634/theoncologist.2016-0254. View

18.

Wu Q, Berglund A, Wang D, Macaulay R, Mule J, Etame A . Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma. Sci Rep. 2019; 9(1):14072. PMC: 6773736. DOI: 10.1038/s41598-019-50489-2. View

19.

Dejaegher J, Solie L, Hunin Z, Sciot R, Capper D, Siewert C . DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol. 2020; 23(2):240-250. PMC: 7906065. DOI: 10.1093/neuonc/noaa247. View

20.

Ma X, Shang F, Zhu W, Lin Q . CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival. Expert Rev Neurother. 2017; 17(9):941-946. DOI: 10.1080/14737175.2017.1351299. View